Magnesium + Taurine

AOR04324

Supports cardiovascular function

  • Helps maintain healthy blood pressure
  • Prevents over-excitability of the central nervous system
  • Provides a correct ratio of magnesium and taurine
Gluten Free
Non-GMO
Vegan

$38.06 or subscribe and save 20%

In stock

Choose a purchase plan:
If you decide a subscription is not for you, it can be cancelled after 30 days.

Magnesium Taurine is an advanced formula for improving overall cardiovascular health.  Taurine and magnesium have both been shown to improve cardiac health, improve insulin sensitivity, and inhibit neuromuscular excitability. They both share similar actions including anti-arrhythmic, antihypertensive and cardio-protective effects. Both magnesium and taurine appear to balance calcium levels in the heart, thus influencing contractility and protecting the heart against potential difficulties caused by an overload of heart calcium levels.

The majority of symptomatic heart patients have relative deficiencies of taurine, therefore restoring the level of taurine would seem essential to any strategy designed to benefit those with heart problems. Magnesium and taurine deficiencies have also been observed in diabetics, trauma patients, individuals requiring long term intravenous feeding and individuals with liver or kidney failure.

Supplementing with magnesium and taurine provides great cardiovascular benefits to these individuals. This combination helps to prevent potentially debilitating deficiencies, stabilize cell membranes, and inhibit the over-excitability of the central nervous system.

AOR Advantage

AOR’s Magnesium Taurate provides a balanced amount of magnesium and taurine. This combination is based on compiled research showing that magnesium and taurine share many similar physiological functions especially in various cardioprotective effects, and that taurine can help fulfill the role of magnesium during deficiencies.

NPN

80043532

Discussion

Magnesium + Taurine helps the body metabolize carbohydrates, proteins, and fats. It also helps maintain proper muscle function, in the development and maintenance of bones and teeth, in tissue formation, and to support cardiovascular function.

Guarantees

AOR™ guarantees that all ingredients have been declared on the label. Contains no wheat, gluten, nuts, peanuts, sesame seeds, sulphites, mustard, soy, dairy, eggs, fish, shellfish or any animal byproduct.

Adult Dosage

Take five capsules daily to support cardiovascular function. To help regulate muscle function, support tissue formation, and to support the metabolism of fat, carbohydrates and protein, take one capsule one to five times daily. Take with or without food, or as directed by a qualified health care practitioner.

Cautions

Consult a health care practitioner prior to use if you are pregnant or breastfeeding.

  • Pharmaceutical synthesis
Main Applications
  • Cardiovascular support
  •  Neurological disorders
Disclaimer

The information and product descriptions appearing on this website are for information purposes only, and are not intended to provide or replace medical advice to individuals from a qualified health care professional. Consult with your physician if you have any health concerns, and before initiating any new diet, exercise, supplement, or other lifestyle changes.

Serving Size: One Capsule
300 mg

Non-medicinal Ingredients: sodium stearyl fumarate. Capsule: hypromellose.

Hypertension

Study #1:

In a 2016 meta-analysis, the antihypertensive effect of oral magnesium supplementation on blood pressure (BP) was performed. It synthesized available evidence from randomized, double-blind, placebo-controlled trials. In total, 34 trials involving 2028 normotensive and hypertensive participants were reviewed. Weighted mean differences of changes in BP and serum Mg were calculated by random-effects meta-analysis. Mg supplementation at a median dose of 368 mg/d for a median duration of three months significantly reduced systolic BP by 2.00 mm Hg (95% confidence interval, 0.43–3.58) and diastolic BP by 1.78 mm Hg (95% confidence interval, 0.73–2.82); these reductions were accompanied by 0.05 mmol/L (95% confidence interval, 0.03, 0.07) elevation of serum Mg compared with placebo. The researchers found that Mg supplementation with a dose of 300 mg/d or duration of one month is sufficient to elevate serum Mg and reduce BP. The findings indicate a causal effect of magnesium supplementation on lowering BPs in adults.

Xi Zhang, Yufeng Li, Liana C. et al. Effects of Magnesium Supplementation on Blood Pressure. Hypertension. 2016;68:324–333 doi.org/10.1161/HYPERTENSIONAHA.116.07664

Study #2:

Mg intake of 500 mg/d to 1000 mg/d may reduce blood pressure (BP) as much as 5.6/2.8 mm Hg. The combination of increased intake of Mg and K coupled with reduced sodium intake is more effective in reducing BP than single mineral intake and is often as effective as one antihypertensive drug in treating hypertension. Magnesium also increases the effectiveness of all antihypertensive drug classes. Preliminary evidence suggests that insulin sensitivity, hyperglycemia, diabetes mellitus, left ventricular hypertrophy, and dyslipidemia may be improved with increased Mg intake. Various genetic defects in magnesium transport are associated with hypertension and possibly with cardiovascular disease. Oral Mg acts as a natural calcium channel blocker, increases nitric oxide, improves endothelial dysfunction, and induces direct and indirect vasodilation.

Houston M. The role of magnesium in hypertension and cardiovascular disease. J Clin Hypertens (Greenwich). 2011;13(11):843-847. doi:10.1111/j.1751-7176.2011.00538.x https://pubmed.ncbi.nlm.nih.gov/22051430/

Study #3

Supplementation with Taurine  prevents the development of hypertension in several animal models. In those models, taurine-mediated reductions in blood pressure appear to be mediated by a combination of diminished [Ca2+]i, oxidative stress, sympathetic activity and inflammatory activity, as well as an improvement in renal function.

Schaffer S, Kim HW. Effects and Mechanisms of Taurine as a Therapeutic Agent. Biomol Ther (Seoul). 2018;26(3):225-241. doi:10.4062/biomolther.2017.251 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5933890/

Stroke, and Cardiovascular Disease (CVD)

Study #1:

A 2018 Editorial of OpenHeart states that Mg plays an important role in cardiovascular health. It is instrumental for the proper maintenance of cellular membrane potential, functioning of the mitochondria and plays a key role in the body’s antioxidative pathways. As a result, Mg deficiency can lead to serious morbidity and mortality, and has been implicated in multiple CVD such as hypertension, cardiomyopathy, cardiac arrhythmia, atherosclerosis, dyslipidaemia and diabetes. Studies have suggested that prompt diagnosis and timely supplementation of Mg may be beneficial in patients with certain cardiac conditions.

DiNicolantonio JJ, Liu J, O’Keefe JHMagnesium for the prevention and treatment of cardiovascular disease. Open Heart 2018;5:e000775. doi: 10.1136/openhrt-2018-000775 https://openheart.bmj.com/content/5/2/e000775

Study #2:

In a 2016 study published in the Journal of the American Heart Association (JAHA) involving 9 824 participants (mean age 65.1 years, 56.8% female) with a median follow‐up of 8.7 years, using a multivariable Cox proportional hazard models, the researchers found that a 0.1 mmol/L increase in serum Mg level was associated with a lower risk for coronary heart disease (CHD) mortality (hazard ratio: 0.82, 95% CI 0.70–0.96). Furthermore, they divided serum magnesium in quartiles, with the second and third quartile combined as reference group (0.81–0.88 mmol/L). Low serum Mg (≤0.80 mmol/L) was associated with an increased risk of CHD mortality (N=431, hazard ratio: 1.36, 95% CI 1.09–1.69) and sudden cardiac death (SCD) (N=217, hazard ratio: 1.54, 95% CI 1.12–2.11). Low serum magnesium was associated with accelerated subclinical atherosclerosis (expressed as increased carotid intima‐media thickness: +0.013 mm, 95% CI 0.005–0.020) and increased QT‐interval, mainly through an effect on heart rate (RR‐interval: −7.1 ms, 95% CI −13.5 to −0.8). Additional adjustments for carotid intima‐media thickness and heart rate did not change the associations with CHD mortality and SCD. Conclusion: Low serum Mg is associated with an increased risk of CHD mortality and SCD.

Kieboom , Brenda C. T. et al. Serum Magnesium and the Risk of Death From Coronary Heart Disease and Sudden Cardiac Death. JAHA January 13, 2016. Vol 5, Issue 1 https://www.ahajournals.org/doi/10.1161/JAHA.115.002707

Study #3:

A 2013 prospective study examined the association between dietary and plasma magnesium and risk of coronary heart disease (CHD) among women in the Nurses’ Health Study. Mg is associated with lower risk of sudden cardiac death, possibly through antiarrhythmic mechanisms. It influences endothelial function, inflammation, blood pressure, and diabetes, but a direct relation with risk of CHD had not been established. Methods and Results: The association for Mg intake was examined among 86 323 women free of disease in 1980. Information on Mg intake and lifestyle factors was ascertained every two to four years through questionnaires. Through 2008, 3614 cases of CHD (2511 nonfatal/1103 fatal) were documented. For plasma Mg, the researchers conducted a nested case–control analysis, with 458 cases of incident CHD (400 nonfatal/58 fatal) matched to controls (1:1) on age, smoking, fasting status, and date of blood sampling. Higher Mg intake was not associated with lower risk of total CHD (P‐linear trend=0.12) or nonfatal CHD (P‐linear trend=0.88) in multivariable models. However, magnesium intake was inversely associated with risk of fatal CHD. The RR comparing quintile five to quintile one of magnesium intake was 0.61 (95% CI, 0.45 to 0.84; P‐linear trend=0.003). The association between magnesium intake and risk of fatal CHD appeared to be mediated partially by hypertension. Plasma magnesium levels above 2.0 mg/dL were associated with lower risk of CHD, although not independent of other cardiovascular biomarkers (RR, 0.67; 95% CI, 0.44 to 1.04). Conclusions: Dietary and plasma magnesium were not associated with total CHD incidence in this population of women. However, magnesium intake was inversely associated with fatal CHD, which may be mediated in part by hypertension.

Chiuve, Stephanie E. Sun , Qi et al. Dietary and Plasma Magnesium and Risk of Coronary Heart Disease Among Women. March 12, 2013, JAHA Vol 2, No.2 https://www.ahajournals.org/doi/10.1161/JAHA.113.000114

Study #4:

The health effects of Taurine have been confirmed epidemiologically by the WHO-coordinated Cardiovascular Diseases and Alimentary Comparison (CARDIAC) Study covering 61 populations in the world. Accumulating evidence from this study indicate that common Taurine intakes reduce CVD risks and contribute to the longevity of the Japanese, which have the lowest coronary heart disease (CHD) mortality in developed countries.

Yamori Y, Liu L, Mori M, Sagara M, Murakami S, Nara Y, Mizushima S. Taurine as the nutritional factor for the longevity of the Japanese revealed by a world-wide epidemiological survey. Adv Exp Med Biol. 2009;643:13–25. https://pubmed.ncbi.nlm.nih.gov/19239132/

Neurological Disorders

Study #1:

In a 2019 study published in the Iran Journal of Public Health, the researchers reviewed the recent literature on magnesium as well as the available data concerning its role in neurological disorders. Several studies have associated Mg deficiency with many neurological disorders such as cerebral vasospasm, Alzheimer’s disease, stroke, and migraine. They concluded that magnesium has demonstrated effects on neurological disorders and that is has been proven useful in cerebral vasospasm, Alzheimer’s disease, Parkinson’s disease, stroke and migraine.

Xue W, You J, Su Y, Wang Q. The Effect of Magnesium Deficiency on Neurological Disorders: A Narrative Review Article. Iran J Public Health. 2019;48(3):379-387. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6570791/

Study #2:

In a recent 2018 review of the literature, researchers have investigated magnesium research across neurological conditions. Current literature has been reviewed for migraine, chronic pain, epilepsy, Alzheimer’s, Parkinson’s, and stroke, as well as the commonly comorbid conditions of anxiety and depression. Magnesium plays an essential role in nerve transmission and neuromuscular conduction. It also functions in a protective role against excessive excitation that can lead to neuronal cell death (excitotoxicity) and has been implicated in multiple neurological disorders. Due to these important functions within the nervous system, Magnesium is a mineral of intense interest for the potential prevention and treatment of neurological disorders. There is strong data to suggest a role for Magnesium in migraine and depression, and emerging data to suggest a protective effect for chronic pain, anxiety, and stroke. More research is needed on magnesium as an adjunct treatment in epilepsy, and to further clarify its role in Alzheimer’s and Parkinson’s. Overall, the mechanistic attributes of magnesium in neurological diseases connote the macromineral as a potential target for neurological disease prevention and treatment.

Kirkland AE, Sarlo GL, Holton KF. The Role of Magnesium in Neurological Disorders. Nutrients. 2018;10(6):730. Published 2018 Jun 6. doi:10.3390/nu10060730 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6024559/#:~:text=From%20a%20neurological%20standpoint%2C%20magnesium,implicated%20in%20multiple%20neurological%20disorders.

Study #3:

Taurine has been considered a potential therapeutic molecule for neurological disorders. It displays extensive inhibitory and regulatory roles that prove its therapeutic efficacy against CNS illnesses. Taurine modulates neurotransmission by acting on several neuroreceptors such as GABA, glutamate and acetylcholine receptors. In addition, it promotes neurogenesis at the preclinical level, and several investigations have reported that it regulates ER stress, energy metabolism, gene expression, quality control processes, Ca2+ homeostasis and osmosis. It shows an emergent therapeutic role against several neurological disorders in designed preclinical studies.

Taurine displayed a protective role against anxiety, depression, neurodegenerative diseases, stroke, epilepsy and diabetic neuropathy. It also protected against trauma- and chemical-mediated neuronal injuries. It has demonstrated ameliorating roles in several models of neurodevelopmental disorders, including Angelman syndrome and Fragile X syndrome, sleep-wake disorders, neural tube defects and attention-deficit hyperactivity disorder. In addition to preclinical studies, taurine played a potential therapeutic role against neuroinflammation, SSADH and stroke at the clinical level. However, more clinical studies necessary to be designed per the preclinical assessment data.

Jakaria M, Azam S, Haque ME, et al. Taurine and its analogs in neurological disorders: Focus on therapeutic potential and molecular mechanisms. Redox Biol. 2019;24:101223. doi:10.1016/j.redox.2019.101223 https://pubmed.ncbi.nlm.nih.gov/31141786/

Study #4:

Taurine is present in the brain, where it appears to be involved in many functions from conception onward. It plays a role in neurotransmission, although the brain does not appear to have a specific Taurine receptor. Studies of synthesis and distribution show that Taurine is present in the brain of the early embryo and is differentially distributed. During the embryonic and early postnatal life, Taurine appears to act as a major inhibitory neurotransmitter/modulator in the brain, having much higher concentrations than GABA in most areas. During the postnatal period, GABA gains dominance along with glycine as central inhibitory transmitters. Because de novo synthesis of Taurine is relatively low in the brain, exogenous Taurine is needed for appropriate development and adult functions of the brain. For instance, perinatal Taurine depletion alters learning, memory, and neural control of blood pressure in adult life, whereas Taurine supplementation prevents or improves some neurological disorders.

Roysommuti, Sanya & Wyss, J.. (2015). Chapter 22. The Effects of Taurine Exposure on the Brain and Neurological Disorders. 10.1016/B978-0-12-411462-3.00022-9. https://www.researchgate.net/publication/282595326_Chapter_22_The_Effects_of_Taurine_Exposure_on_the_Brain_and_Neurological_Disorders

Brain Injury

Study #1:

This 2018 study aims at investigating the protective effect of Taurine against inflammation, apoptosis and oxidative stress in traumatic brain injury. Taurine plays a critical nutritional role in brain cell growth, differentiation, and development. It is involved in regeneration and neuroprotection in the injured nervous system, and is an effective antioxidant against lead‑, cadmium‑, and exercise‑induced oxidative stress. Astrocytes and neuron cells were co‑cultured and cells were treated with different concentrations of taurine (100, 200 and 300 mg/l) for 72 h, and the levels of reactive oxygen species (ROS), malondialdehyde, reduced glutathione, glutathione peroxidase, superoxide dismutase, catalase, acetylcholinesterase, tumor necrosis factor‑α, interleukin‑6, caspase‑3, p53, B‑cell lymphoma 2 and Bcl‑2‑associated X protein were determined. These inflammatory, apoptotic, and oxidative stress markers were substantially increased in injured cells and returned to normal levels following taurine supplementation. Thus, taurine supplementation may be effective against oxidative stress, apoptosis, and inflammation in injured brain cells.

Niu, X., Zheng, S., Liu, H., & Li, S. (2018). Protective effects of taurine against inflammation, apoptosis, and oxidative stress in brain injury. Molecular Medicine Reports, 18, 4516-4522. https://doi.org/10.3892/mmr.2018.9465

Study #2:

In a 2018 study published in Journal of Hazardous Materials, researchers were looking to identify novel compounds to protect against radiation-induced brain injury. Exposure to ionizing radiation (IR) is inevitable since over 80% of total average exposure comes from natural sources. Brain is vulnerable to the deleterious effects of IR. Adult male albino rats weighing 120–150 g were divided into five groups of 18 rats each. Group one served as control; group two received an oral daily dose of Taurine (500 mg/kg) for two weeks and group three was exposed to a whole-body single dose of γ-irradiation (six Gy). Groups four and five received Taurine  before and after γ-irradiation, respectively. Six rats from each group were sacrificed after one, two or three weeks. Throughout the three weeks studied, there were significant increases in MDA, NO, TNF-α levels, and Cytochrome-c and activities of Caspases -9 and -3 and significant decreases in GSH, SOD, CAT and GPx in the irradiated group when compared with the relevant control. Cerebral cortex of irradiated rats showed vacuolization and nuclear pyknosis in the neuronal cells and focal gliosis. Taurine  administration pre- or post-irradiation significantly ameliorated all these previous effects. Taurine had antioxidant, anti-inflammatory, and anti-apoptotic effects and ameliorated the histopathological changes in brain in a time-dependent model.

El-Maraghi, Engy F., Abdel-Fattah, Kamal I., Soliman, Saeed M., et al. (2018). Taurine provides a time-dependent amelioration of the brain damage induced by γ-irradiation in rats. Journal of Hazardous Materials, 40-46. doi:101016/jjhazmat201807005 https://www.sciencedirect.com/science/article/abs/pii/S0304389418305168?via%3Dihub